Dennis G McGonagle Selected Research

Aminopeptidases

1/2023

EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dennis G McGonagle Research Topics

Disease

6	Psoriatic Arthritis 01/2023 - 09/2013
5	COVID-19 01/2022 - 01/2021
5	Inflammation (Inflammations) 01/2021 - 07/2008
3	Rheumatoid Arthritis 12/2023 - 12/2014
3	Necrosis 01/2020 - 01/2019
2	Arthralgia (Joint Pain) 12/2023 - 01/2018
2	Arthritis (Polyarthritis) 12/2023 - 01/2020
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2023 - 01/2020
2	Synovitis 01/2022 - 01/2018
2	Ankylosing Spondylitis 01/2019 - 09/2013
2	Axial Spondyloarthritis 01/2019 - 09/2013
2	Edema (Dropsy) 09/2013 - 07/2008
1	Asthma (Bronchial Asthma) 12/2023
1	Uveitis 01/2023
1	Osteoarthritis 01/2022
1	Infections 01/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020
1	Adult-Onset Still's Disease 01/2020
1	Pneumocystis Infections 01/2020
1	Spondylarthropathies 01/2019
1	Nail Diseases (Nail Disease) 01/2018
1	Enthesopathy 01/2018
1	Pain (Aches) 01/2018
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 04/2016
1	Lymphoma (Lymphomas) 12/2014
1	Fibrosis (Cirrhosis) 11/2013
1	Muscular Diseases (Myopathy) 02/2012
1	Joint Diseases (Joint Disease) 12/2007

Drug/Important Bio-Agent (IBA)

4	InterleukinsIBA 12/2023 - 01/2019
4	GlucocorticoidsIBA 01/2022 - 01/2020
3	Immunologic Factors (Immunomodulators)IBA 01/2022 - 01/2021
3	baricitinibIBA 01/2022 - 01/2020
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2008
2	tocilizumab (atlizumab)FDA Link 01/2022 - 10/2021
2	tofacitinibIBA 01/2022 - 10/2021
2	Antirheumatic Agents (DMARD)IBA 01/2022 - 01/2020
2	Janus Kinase InhibitorsIBA 01/2022 - 10/2021
2	Oxygen (Dioxygen)IBA 01/2022 - 01/2021
2	Immunomodulating AgentsIBA 10/2021 - 01/2021
2	CytokinesIBA 01/2021 - 01/2019
2	AntibodiesIBA 01/2021 - 02/2012
2	Interleukin-23 (Interleukin 23)IBA 01/2020 - 11/2019
1	benralizumabIBA 12/2023
1	Anti-Citrullinated Protein AntibodiesIBA 12/2023
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 12/2023
1	mepolizumabIBA 12/2023
1	Rheumatoid FactorIBA 12/2023
1	Histocompatibility Antigens Class IIBA 01/2023
1	AminopeptidasesIBA 01/2023
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Interleukin-1 (Interleukin 1)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	InterferonsIBA 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021
1	apremilastIBA 01/2020
1	Janus Kinase 1IBA 01/2020
1	amsonic acid (DAS)IBA 01/2020
1	Interleukin-12 (IL 12)IBA 01/2020
1	guselkumabIBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	Tumor Necrosis Factor InhibitorsIBA 01/2018
1	SteroidsIBA 04/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2014
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 09/2013
1	Cholinergic ReceptorsIBA 02/2012

Therapy/Procedure

7	Therapeutics 12/2023 - 12/2007
5	Immunomodulation 01/2022 - 01/2021
1	Transplantation 01/2023
1	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2022
1	Injections 01/2020
1	Biological Therapy 01/2018